To include your compound in the COVID-19 Resource Center, submit it here.

Staccato loxapine regulatory update

Alexza plans to resubmit an NDA for Staccato loxapine (AZ-004) to treat agitation in patients with schizophrenia or bipolar disorder

Read the full 209 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE